Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 25, 2026, 3:15 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1273–1296 of 21,205 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Immunity Disorders Clear all
Terminated Phase 3 Interventional Results available

Canakinumab to Treat Neonatal-Onset Multisystem Inflammatory Disease

NCT00770601
View directory record Official record
Conditions
NOMID, CINCA Syndrome
Interventions
Canakinumab
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
2 Years to 25 Years
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jun 10, 2021 · Synced Oct 25, 2026, 3:15 PM EDT
Completed Phase 1 Interventional

Study to Investigate the Safety and Tolerability of Odronextamab in Patients With CD20+ B-Cell Malignancies

NCT02290951
View directory record Official record
Conditions
Non-Hodgkin Lymphoma, Chronic Lymphocytic Leukemia
Interventions
Odronextamab multiple dose levels
Drug
Lead sponsor
Regeneron Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2025
U.S. locations
10
States / cities
Orange, California • Stanford, California • Tampa, Florida + 4 more
Source: ClinicalTrials.gov public record
Updated Oct 10, 2025 · Synced Oct 25, 2026, 3:15 PM EDT
Completed Phase 1 Interventional

Arsenic Trioxide and Ascorbic Acid Combined With Bortezomib, Thalidomide, and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma or Plasma Cell Leukemia

NCT00258245
View directory record Official record
Conditions
Multiple Myeloma and Plasma Cell Neoplasm
Interventions
ascorbic acid, arsenic trioxide, bortezomib, dexamethasone, thalidomide, Aspirin
Dietary Supplement · Drug
Lead sponsor
Barbara Ann Karmanos Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
1
States / cities
Detroit, Michigan
Source: ClinicalTrials.gov public record
Updated Apr 29, 2013 · Synced Oct 25, 2026, 3:15 PM EDT
Completed Phase 3 Interventional

A Collaborative Model to Improve Blood Pressure (BP) Control and Minimize Racial Disparities

NCT00935077
View directory record Official record
Conditions
Hypertension, Asthma
Interventions
PPCM Asthma, 24 Month PPCM BP, 9 Month PPCM BP
Other
Lead sponsor
University of Iowa
Other
Eligibility
18 Years and older
Enrollment
1,441 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
28
States / cities
San Diego, California • Hartford, Connecticut • Gainesville, Florida + 25 more
Source: ClinicalTrials.gov public record
Updated Jul 10, 2014 · Synced Oct 25, 2026, 3:15 PM EDT
Completed No phase listed Observational

Perioperative Flare in RA: Characterization of Clinical and Biological Features

NCT02111057
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
Not listed
Lead sponsor
Hospital for Special Surgery, New York
Other
Eligibility
18 Years to 90 Years
Enrollment
162 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Oct 21, 2019 · Synced Oct 25, 2026, 3:15 PM EDT
Completed Phase 4 Interventional

Long-Term Lamivudine Therapy for Chronic Hepatitis B

NCT00120354
View directory record Official record
Conditions
Hepatitis B, Chronic
Interventions
Blood Testing, Percutaneous Liver Biopsy, Lamivudine Therapy
Procedure
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 2, 2017 · Synced Oct 25, 2026, 3:15 PM EDT
Completed Phase 1Phase 2 Interventional

Combination Chemotherapy in Treating Patients With Advanced Cancer

NCT00004105
View directory record Official record
Conditions
Leukemia, Lymphoma, Sarcoma, Unspecified Adult Solid Tumor, Protocol Specific
Interventions
estramustine phosphate sodium, paclitaxel, vinorelbine ditartrate
Drug
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1998
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 28, 2011 · Synced Oct 25, 2026, 3:15 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Breathing Exercises for Asthma

NCT02151422
View directory record Official record
Conditions
Asthma
Interventions
Breathing exercise
Behavioral
Lead sponsor
University of Michigan
Other
Eligibility
18 Years to 65 Years
Enrollment
75 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2015
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Jun 30, 2016 · Synced Oct 25, 2026, 3:15 PM EDT
Terminated Not applicable Interventional

Pharmacists Coordinated Care Oncology Model (PCOM) for Patients Taking Oral Anti-cancer Medications

NCT04595851
View directory record Official record
Conditions
Chronic Myeloid Leukemia, Chronic Lymphocytic Leukemia, Multiple Chronic Conditions
Interventions
Patient Reported Outcome Measure (PROM), Comprehensive Medication Review (CMR), Communications between oncology and primary care pharmacists
Other
Lead sponsor
University of Michigan Rogel Cancer Center
Other
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Nov 22, 2022 · Synced Oct 25, 2026, 3:15 PM EDT
Recruiting Phase 2 Interventional

A Phase 2 Study to Evaluate Povetacicept in Adults With Generalized Myasthenia Gravis

NCT07501702
View directory record Official record
Conditions
Myasthenia Gravis, Generalized
Interventions
Povetacicept, Placebo
Drug
Lead sponsor
Vertex Pharmaceuticals Incorporated
Industry
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
15
States / cities
Mission Hills, California • Boca Raton, Florida • Homestead, Florida + 10 more
Source: ClinicalTrials.gov public record
Updated Sep 11, 2026 · Synced Oct 25, 2026, 3:15 PM EDT
Terminated Phase 2 Interventional Results available

ASCEND GO-2: Study of RVT-1401 for the Treatment of Participants With Active, Moderate to Severe Graves' Ophthalmopathy ( GO )

NCT03938545
View directory record Official record
Conditions
Graves' Ophthalmopathy (GO)
Interventions
RVT-1401 (Administered via subcutaneous injection), Placebo (Administered via subcutaneous injection)
Drug · Other
Lead sponsor
Immunovant Sciences GmbH
Industry
Eligibility
18 Years and older
Enrollment
65 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
12
States / cities
Beverly Hills, California • Pasadena, California • Miami, Florida + 9 more
Source: ClinicalTrials.gov public record
Updated Sep 22, 2022 · Synced Oct 25, 2026, 3:15 PM EDT
Completed Phase 4 Interventional Results available

Safety and Tolerability of Higher Infusion Parameters of IgPro20 (Hizentra) in Subjects With Primary Immunodeficiency (PID)

NCT03033745
View directory record Official record
Conditions
Primary Immunodeficiency
Interventions
IgPro20
Drug
Lead sponsor
CSL Behring
Industry
Eligibility
2 Years and older
Enrollment
49 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
10
States / cities
Birmingham, Alabama • Litchfield Park, Arizona • St. Petersburg, Florida + 7 more
Source: ClinicalTrials.gov public record
Updated Mar 25, 2020 · Synced Oct 25, 2026, 3:15 PM EDT
Recruiting Early Phase 1 Interventional Accepts healthy volunteers

Effect of C-peptide on Hypoglycemic Counterregulation

NCT06470295
View directory record Official record
Conditions
Hypoglycemia, Type 1 Diabetes
Interventions
Saline, C-peptide
Other · Biological
Lead sponsor
University of Cincinnati
Other
Eligibility
18 Years to 40 Years
Enrollment
38 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2028
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Feb 17, 2026 · Synced Oct 25, 2026, 3:15 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Blood Collection From Individuals With Lung Disease for Genetic Studies

NCT00362739
View directory record Official record
Conditions
Asthma, COPD, Interstitial Lung Disease, Cystic Fibrosis, Lung Cancer
Interventions
Not listed
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
18 Years and older
Enrollment
3,087 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2015
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 29, 2016 · Synced Oct 25, 2026, 3:15 PM EDT
Not listed Phase 1 Interventional Accepts healthy volunteers

Collaborative Study Of Neurofeedback Training Of 6-18 Year Olds With Autism

NCT01154777
View directory record Official record
Conditions
Autism
Interventions
Neurofeedback training
Behavioral
Lead sponsor
Institute for Personal Excellence, P.A.
Other
Eligibility
6 Years to 18 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2016
U.S. locations
2
States / cities
Raleigh, North Carolina
Source: ClinicalTrials.gov public record
Updated Oct 5, 2010 · Synced Oct 25, 2026, 3:15 PM EDT
Completed Phase 2 Interventional Results available

Effect of KB003 in Subjects With Asthma Inadequately Controlled by Corticosteroids

NCT01603277
View directory record Official record
Conditions
Moderate-to-Severe Asthma
Interventions
Anti-GM-CSF Monoclonal Antibody 400mg, Placebo
Biological · Other
Lead sponsor
Humanigen, Inc.
Industry
Eligibility
16 Years to 75 Years
Enrollment
160 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
33
States / cities
Birmingham, Alabama • Fullerton, California • Granada Hills, California + 27 more
Source: ClinicalTrials.gov public record
Updated Feb 2, 2015 · Synced Oct 25, 2026, 3:15 PM EDT
Terminated Phase 1 Interventional

Phase 1 Study of Terameprocol (EM-1421) in Patients With Leukemia

NCT00664677
View directory record Official record
Conditions
Leukemias, Acute Myeloid Leukemia (AML), Acute Lymphocytic Leukemia (ALL), Adult T Cell Leukemia (ATL), Chronic Myeloid Leukemia (CML-BP), Chronic Lymphocytic Leukemia (CLL), Myelodysplastic Syndrome (MDS), Chronic Myelomonocytic Leukemia (CMML)
Interventions
Terameprocol (EM-1421)
Drug
Lead sponsor
Erimos Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Feb 23, 2016 · Synced Oct 25, 2026, 3:15 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Bioequivalence Study to Assess Systemic Exposure of FP and SAL FDC From Different DPIs

NCT02215122
View directory record Official record
Conditions
Asthma, COPD
Interventions
MGR001, Advair® Diskus®, Seretide™ Accuhaler™
Drug
Lead sponsor
Mylan Pharma UK Ltd.
Industry
Eligibility
18 Years to 55 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Mar 7, 2022 · Synced Oct 25, 2026, 3:15 PM EDT
Withdrawn Phase 1 Interventional

Gene-Modified HIV-Protected Stem Cell Transplant in Treating Patients With HIV-Associated Lymphoma

NCT02378922
View directory record Official record
Conditions
AIDS-Related Hodgkin Lymphoma, AIDS-Related Non-Hodgkin Lymphoma, HIV Infection, Recurrent Hodgkin Lymphoma, Recurrent Non-Hodgkin Lymphoma
Interventions
Gene-Modified HIV-Protected Hematopoietic Stem Cells, Laboratory Biomarker Analysis, Transplant Conditioning
Biological · Other
Lead sponsor
Fred Hutchinson Cancer Center
Other
Eligibility
18 Years to 66 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Dec 27, 2018 · Synced Oct 25, 2026, 3:15 PM EDT
Withdrawn Early Phase 1 Interventional

Melphalan on Disease Burden Measured by Next Generation Sequencing Before AHCT (Autologous Hematopoietic Cell Transplant) for Multiple Myeloma

NCT05013437
View directory record Official record
Conditions
Multiple Myeloma
Interventions
Evomela, Next Generation Sequencing, Prochlorperazine, Acetaminophen, Diphenhydramine
Drug · Device
Lead sponsor
Koen van Besien
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Apr 2, 2024 · Synced Oct 25, 2026, 3:15 PM EDT
Terminated Phase 3 Interventional Results available

A Randomized Controlled Trial of Eculizumab in AQP4 Antibody-positive Participants With NMO (PREVENT Study)

NCT01892345
View directory record Official record
Conditions
Neuromyelitis Optica, Neuromyelitis Optica Spectrum Disorder
Interventions
Eculizumab, Placebo
Drug
Lead sponsor
Alexion Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
143 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
19
States / cities
Scottsdale, Arizona • Carlsbad, California • Washington D.C., District of Columbia + 15 more
Source: ClinicalTrials.gov public record
Updated Jun 26, 2019 · Synced Oct 25, 2026, 3:15 PM EDT
Completed Phase 2 Interventional

Oral Collagen for Rheumatoid Arthritis

NCT00000401
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
Oral bovine type II collagen
Drug
Lead sponsor
University of Tennessee
Other
Eligibility
18 Years to 80 Years
Enrollment
110 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2005
U.S. locations
2
States / cities
Jackson, Tennessee • Memphis, Tennessee
Source: ClinicalTrials.gov public record
Updated May 29, 2013 · Synced Oct 25, 2026, 3:15 PM EDT
Completed Phase 2 Interventional

Islet Cell Transplantation Alone and CD34+ Enriched Bone Marrow Cell Infusion in Patients With Diabetes Mellitus: Steroid-Free Regimen

NCT00021801
View directory record Official record
Conditions
Type 1 Diabetes Mellitus
Interventions
Islet Cell Transplantation
Procedure
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Eligibility
18 Years to 50 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Mar 2, 2010 · Synced Oct 25, 2026, 3:15 PM EDT
Recruiting No phase listed Observational

SCOPE: Observational Study of the Consequences of the Protease Inhibitor Era

NCT00187512
View directory record Official record
Conditions
HIV Infections
Interventions
Not listed
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older
Enrollment
2,500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2033
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Sep 8, 2026 · Synced Oct 25, 2026, 3:15 PM EDT